

genOway signs a contract for up to 2 Million USD in intended services with a US-based leading biopharmaceutical firm

Lyon, France - October 17th, 2007

genOway, the biotechnology company dedicated to the development of genetically modified animal models reports the signing of a contract for up to 2 Million USD in intended services with a leading biopharmaceutical company based in the United States of America. Under the terms of this 2-year agreement, genOway will provide its client with customized genetically modified mouse lines tailored to the researchers' needs. Moreover, this agreement can be increased to include additional models.

genOway has been chosen thanks to the company's expertise and capacity to create highly sophisticated animal models by means of an industrialized production process

"This contract is the second multi-million dollar deal of the year for genOway. It further confirms that the company is able to propose acceptable offers to large biopharmaceutical companies. genOway is proud to have been chosen by this company and we are very excited about the start of this collaboration" said **Alexandre Fraichard, CEO of genOway.**

"This deal reinforces genOway's position as a major player for leading biopharmaceutical companies in the world" said **Kader Thiam, Director of Transgenic Technologies of genOway**

About genOway:

genOway (ALTERNEXT-NYSE: ALGEN) is a biotechnology company dedicated to the development of genetically modified animal models aimed at enhancing the security and relevancy of *in vivo* research projects. Focusing its effort on the mouse and rat, genOway's expertise combined transgenic technologies such as pronuclear microinjection, Knock-out, Knock-in, Knock-down, point mutation, humanization combined with innovative patented technologies adapted to target validation, *in vivo* drug screening, drug efficacy and safety testing program. Collaborations with worldwide leaders (Charles River Laboratories, Invitrogen, Tet systems, etc..) enable genOway to provide its customer with a complete portfolio of products and services for all aspects of model generation and characterization. Operating in 22 countries in Europe, North America and Asia, genOway has developed more than 450 rat and mouse lines for 40 companies and 160 research institutions. Thanks to its industrialized production facilities, genOway is involved in large-scale projects with several academic centers (German National Genome Research Network, University College London, King's College London, Max Planck Institute) and with pharmaceutical companies (Bayer Corp, Boehringer Ingelheim, Johnson & Johnson). For more information consult: www.genoway.com

Contact for press information:

Marie Norbert - genOway - norbert@genoway.com

Contact for investors:

Gilles de Poncins , CFO - genOway - finances@genoway.com